Journal
CARDIOVASCULAR DIABETOLOGY
Volume 13, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1475-2840-13-26
Keywords
Residual cardiovascular risk; Atherogenic dyslipidaemia; Type 2 diabetes; Therapeutic options
Funding
- Pfizer
- Sanofi
- Bristol-Myers-Squibb
- Merck
- AstraZeneca
- Boehringer Ingelheim
- French government
- GlaxoSmithKline
- MSD
- Genzyme
- Aegerion
- Montreal University
- Eli Lilly Co
- Abbott
- Amgen
- Kowa
- Merck and Co.
- Novartis
- Recordati
- Roche
- Sanofi-Aventis
- Lilly
- Sanofi-Regeneron
- Sanofi-Genzyme
- Boehringer
- Janssen
- Eli Lilly
- LifeScan
- Menarini
- Novo Nordisk
- Takeda
- Kowa Co.Ltd
- Bayer
- Daiichi Sankyo
- Astellas
- Mitsubishi Tanabe
- Fournier
Ask authors/readers for more resources
Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of obesity, metabolic syndrome and type 2 diabetes. While best standards of care, including high-dose statins, can ameliorate the risk of vascular complications, patients remain at high risk of cardiovascular events. The Residual Risk Reduction Initiative (R(3)i) has previously highlighted atherogenic dyslipidaemia, defined as the imbalance between proatherogenic triglyceride-rich apolipoprotein B-containing-lipoproteins and antiatherogenic apolipoprotein A-I-lipoproteins (as in high-density lipoprotein, HDL), as an important modifiable contributor to lipid-related residual cardiovascular risk, especially in insulin-resistant conditions. As part of its mission to improve awareness and clinical management of atherogenic dyslipidaemia, the R(3)i has identified three key priorities for action: i) to improve recognition of atherogenic dyslipidaemia in patients at high cardiometabolic risk with or without diabetes; ii) to improve implementation and adherence to guideline-based therapies; and iii) to improve therapeutic strategies for managing atherogenic dyslipidaemia. The R(3)i believes that monitoring of non-HDL cholesterol provides a simple, practical tool for treatment decisions regarding the management of lipid-related residual cardiovascular risk. Addition of a fibrate, niacin (North and South America), omega-3 fatty acids or ezetimibe are all options for combination with a statin to further reduce non-HDL cholesterol, although lacking in hard evidence for cardiovascular outcome benefits. Several emerging treatments may offer promise. These include the next generation peroxisome proliferator-activated receptor alpha agonists, cholesteryl ester transfer protein inhibitors and monoclonal antibody therapy targeting proprotein convertase subtilisin/kexin type 9. However, long-term outcomes and safety data are clearly needed. In conclusion, the R(3)i believes that ongoing trials with these novel treatments may help to define the optimal management of atherogenic dyslipidaemia to reduce the clinical and socioeconomic burden of residual cardiovascular risk.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available